Allergan PLC (AGN)

NYSE
Currency in USD
193.02
0.00(0.00%)
Closed·
Showing Allergan historical data. For real-time data please try another search
Day's Range
191.64193.38
52 wk Range
0.00193.38
Key Statistics
Edit
Prev. Close
192.99
Open
193.01
Day's Range
191.64-193.38
52 wk Range
0-0
Volume
-
Average Volume (3m)
3.08M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Allergan PLC News & Analysis

Show more

Allergan PLC Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer’s disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.

Employees
17400

Allergan PLC Earnings Call Summary for Q4/2024

  • IFRS operating result stable at €1.5 billion; proposed dividend increase of 17%; €150 million share buyback program underway
  • Strong growth in U.S. mid-sized retirement plans and World Financial Group network; challenges in China due to low interest rates
  • Targeting operating capital generation of €1.2 billion and free cash flow of €800 million by 2025; dividend aim of €0.35 per share
  • CEO confident in meeting 2025 targets; focus on growing strategic assets and reducing exposure to financial assets
  • Stock shows strong momentum with 27% YTD return; company appears slightly overvalued according to InvestingPro analysis
Last Updated: 2025/02/20, 11:14
Read Full Transcript

Earnings

Latest Release
Aug 04, 2020
EPS / Forecast
-- / 3.71
Revenue / Forecast
-- / 3.60B
EPS Revisions
Last 90 days

AGN Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.